reference scaled bioequivalence [RSABE / ABEL]

posted by AngusMcLean – USA, 2010-11-07 15:55 (5304 d 00:28 ago) – Posting: # 6111
Views: 15,813

Sunday November 7, 201:

I discovered this slide from a presentation from Pharsight

From: 80-125% to ± 1.25σ(Ref)/0.25I understand it is an interpretation of the direction of FDA thinking relating to extending the criteria for means ratio and confidence intervals for BE of highly variable drugs.;-)

The observed ratio must be within 80-125%; the study design must be partially or fully replicated.

What do you think of it?

Angus


Edit: Category changed. [Helmut]

Complete thread:

UA Flag
Activity
 Admin contact
23,424 posts in 4,927 threads, 1,672 registered users;
95 visitors (0 registered, 95 guests [including 6 identified bots]).
Forum time: 17:23 CEST (Europe/Vienna)

A statistical analysis, properly conducted, is a delicate dissection of
uncertainties, a surgery of suppositions.    Micheal J. Moroney

The Bioequivalence and Bioavailability Forum is hosted by
BEBAC Ing. Helmut Schütz
HTML5